651 related articles for article (PubMed ID: 25847075)
1. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
Hussar DA; Kaminski JL
J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
[No Abstract] [Full Text] [Related]
4. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
5. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
6. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
8. [Progress of research and development of MAPK pathway inhibitors].
Ishii N
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):15-21. PubMed ID: 23302943
[No Abstract] [Full Text] [Related]
9. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
Zaloum A; Falet JR; Elkrief A; Chalk C
Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
[No Abstract] [Full Text] [Related]
10. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
12. Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
Laske J; Meier F; Bauer A; Beissert S; Garzarolli M
Melanoma Res; 2018 Oct; 28(5):485-487. PubMed ID: 30148769
[No Abstract] [Full Text] [Related]
13. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
[No Abstract] [Full Text] [Related]
14. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib and its potential for the treatment of metastatic melanoma.
Menzies AM; Long GV; Murali R
Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089
[TBL] [Abstract][Full Text] [Related]
16. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
Sawada H; Kanehisa F; Katoh N; Asai J
J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
[No Abstract] [Full Text] [Related]
17. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.
Martín Algarra S; Soriano V; Fernández-Morales L; Berciano-Guerrero MÁ; Mujika K; Manzano JL; Puértolas Hernández T; Soria A; Rodríguez-Abreu D; Espinosa Arranz E; Medina Martínez J; Márquez-Rodas I; Rubió-Casadevall J; Ortega ME; Jurado García JM; Lecumberri Biurrun MJ; Palacio I; Rodríguez de la Borbolla Artacho M; Altozano JP; Castellón Rubio VE; García A; Luna P; Ballesteros A; Fernández O; López Martín JA; Berrocal A; Arance A
Medicine (Baltimore); 2017 Dec; 96(52):e9523. PubMed ID: 29384960
[TBL] [Abstract][Full Text] [Related]
19. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
